Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.
Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...
If PIFELTRO is coadministered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart). Consult the full Prescribing Information prior to and during treatment ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
Researchers at University Hospital Zurich and the University of Zurich report that intimate physical contact combined with ...
She was shocked to see her hand become red and swollen: "A silly paper cut did all this!" It’s a reminder all cuts can become ...
Cases of scabies – a parasitic skin condition once associated with poor hygiene and crowded living conditions – are on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback